Both well-established pharmaceutical companies and new start-up biotech companies are racing to create CRISPR-based therapeutics. Compared to other strategies for gene therapy, CRISPR genome editing is thought to be faster, less expensive, and potentially far safer. Autologous CRISPR cell therapies that use genome editing to correct a mutation in a patient’s own cells hold promise in circumventing the rejection issues present with transplant therapies that require donor matching. CRISPR genome editing is especially promising for diseases that can be tackled by modifying cells that can easily be removed from a patient, which allows for additional screening to ensure no off-target genome modifications during genome-editing.

CRISPR Services

REQUEST A QUOTE

Do you like the current new website?

Hate

Dislike

Neutral

Like

Love

*